X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with REDINGTON (INDIA) - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs REDINGTON (INDIA) - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

REDINGTON (INDIA) 
   Change

Redington India, incorporated in 1961, commenced the operations in 1993 distributing information technology (IT) products. Now the company along with its subsidiaries is in the business of end-to-end supply chain management of IT and non- IT products... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES REDINGTON (INDIA) INDOCO REMEDIES/
REDINGTON (INDIA)
 
P/E (TTM) x 34.8 19.0 182.8% View Chart
P/BV x 4.1 3.1 131.7% View Chart
Dividend Yield % 0.5 1.0 53.7%  

Financials

 INDOCO REMEDIES   REDINGTON (INDIA)
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
REDINGTON (INDIA)
Mar-15
INDOCO REMEDIES/
REDINGTON (INDIA)
5-Yr Chart
Click to enlarge
High Rs360136 264.4%   
Low Rs249120 207.9%   
Sales per share (Unadj.) Rs119.0789.5 15.1%  
Earnings per share (Unadj.) Rs8.49.7 86.5%  
Cash flow per share (Unadj.) Rs15.210.7 141.9%  
Dividends per share (Unadj.) Rs1.601.90 84.2%  
Dividend yield (eoy) %0.51.5 35.4%  
Book value per share (Unadj.) Rs70.759.4 119.0%  
Shares outstanding (eoy) m92.15399.70 23.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.60.2 1,578.6%   
Avg P/E ratio x36.413.2 275.2%  
P/CF ratio (eoy) x20.011.9 167.8%  
Price / Book Value ratio x4.32.2 199.9%  
Dividend payout %19.119.6 97.4%   
Avg Mkt Cap Rs m28,08351,182 54.9%   
No. of employees `0006.0NA-   
Total wages/salary Rs m2,1674,677 46.3%   
Avg. sales/employee Rs Th1,817.0NM-  
Avg. wages/employee Rs Th359.0NM-  
Avg. net profit/employee Rs Th127.7NM-  
INCOME DATA
Net Sales Rs m10,968315,549 3.5%  
Other income Rs m40678 5.9%   
Total revenues Rs m11,007316,227 3.5%   
Gross profit Rs m1,5656,940 22.5%  
Depreciation Rs m633426 148.6%   
Interest Rs m621,586 3.9%   
Profit before tax Rs m9095,606 16.2%   
Minority Interest Rs m0-238 0.0%   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m0-52 0.0%   
Tax Rs m1391,450 9.6%   
Profit after tax Rs m7713,865 19.9%  
Gross profit margin %14.32.2 648.7%  
Effective tax rate %15.325.9 58.9%   
Net profit margin %7.01.2 573.7%  
BALANCE SHEET DATA
Current assets Rs m5,72580,200 7.1%   
Current liabilities Rs m5,45456,447 9.7%   
Net working cap to sales %2.57.5 32.8%  
Current ratio x1.01.4 73.9%  
Inventory Days Days6233 188.4%  
Debtors Days Days7251 140.4%  
Net fixed assets Rs m5,3072,152 246.7%   
Share capital Rs m184799 23.1%   
"Free" reserves Rs m6,33120,810 30.4%   
Net worth Rs m6,51623,742 27.4%   
Long term debt Rs m1,3231,011 130.9%   
Total assets Rs m11,97083,829 14.3%  
Interest coverage x15.64.5 345.0%   
Debt to equity ratio x0.20 477.1%  
Sales to assets ratio x0.93.8 24.3%   
Return on assets %7.06.5 107.0%  
Return on equity %11.816.3 72.7%  
Return on capital %12.427.9 44.4%  
Exports to sales %00 0.0%   
Imports to sales %04.0 0.0%   
Exports (fob) Rs mNA106 0.0%   
Imports (cif) Rs mNA12,758 0.0%   
Fx inflow Rs m4,507863 522.5%   
Fx outflow Rs m1,14113,108 8.7%   
Net fx Rs m3,366-12,245 -27.5%   
CASH FLOW
From Operations Rs m8862,568 34.5%  
From Investments Rs m-1,706-55 3,078.5%  
From Financial Activity Rs m1,316-2,249 -58.5%  
Net Cashflow Rs m497264 187.8%  

Share Holding

Indian Promoters % 59.2 0.0 -  
Foreign collaborators % 0.0 21.0 -  
Indian inst/Mut Fund % 12.5 7.5 166.7%  
FIIs % 6.0 37.3 16.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 34.1 65.7%  
Shareholders   12,805 14,740 86.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   STC INDIA  MOTILAL OSWAL  ADANI PORTS & SEZ  KOTHARI PRODUCTS  CHOLAMANDALAM INVEST.  



Today's Market

Sensex Surges 300 Points; Tata Steel Up 3.5%(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading near all-time high levels. Sectoral indices are trading on a positive note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Jan 23, 2018 03:34 PM

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - REDINGTON (INDIA) COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS